Repositioning generic drugs: Empirical Findings & Policy Implications
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- Fulltext
Final published version, 930 KB, PDF document
Commentators claim that drug repositioning (ie developing new uses for authorised drugs) significantly slows when generics are authorised and, therefore, law reform is necessary to encourage more R&D. This study empirically examines this claim by analysing records of clinical trials. It finds that once generics are authorised: i) commercial trials continue at ‘active’ rates for approximately half of the drugs studied, and ii) the number of hospital and university trials actually increases. These findings cast doubt on whether additional incentives are needed. They also indicate that a more effective way to reposition drugs is for recently established government programmes to embrace IP strategies and leverage the hospital and university trials as an R&D pipeline.
Keywords: drug repositioning, patent law, regulatory protection, clinical trials, empirical study, generic drugs.
Keywords: drug repositioning, patent law, regulatory protection, clinical trials, empirical study, generic drugs.
Original language | English |
---|---|
Journal | IIC International Review of Intellectual Property and Competition Law |
Volume | 53 |
Issue number | 9 |
Pages (from-to) | 1287-1322 |
Number of pages | 36 |
ISSN | 0018-9855 |
DOIs | |
Publication status | Published - 2022 |
Number of downloads are based on statistics from Google Scholar and www.ku.dk
No data available
ID: 306454713